896127-80-3

Basic information

• Product Name: 5-Chloro-2-methoxybenzenemethanamine
• Synonyms: 5-Chloro-2-methoxybenzenemethanamine;(4-chloro-2-Methoxyphenyl)MethanaMine;4-Chloro-2-methoxy-benzenemethanamine;4-Chloro-2-methoxybenzylamine
• CAS NO: 896127-80-3
• Molecular Formula: C8H10ClNO
• Molecular Weight: 171.62
• Mol File: 896127-80-3.mol

Chemical Properties

• Boiling Point: 252.785 °C at 760 mmHg
• Flash Point: 106.681 °C
• Appearance: /
• Density: 1.181 g/cm³
• Vapor Pressure: 0.019mmHg at 25°C
• Refractive Index: 1.55
• CAS DataBase Reference: 5-Chloro-2-methoxybenzenemethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Chloro-2-methoxybenzenemethanamine(896127-80-3)
• EPA Substance Registry System: 5-Chloro-2-methoxybenzenemethanamine(896127-80-3)

Safety Data

• Hazardous Substances Data: 896127-80-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Chloro-2-methoxybenzenemethanamine is used as an intermediate in the synthesis of various pharmaceutical compounds for its ability to participate in multiple chemical reactions, contributing to the development of new drugs.
Used in Chemical Industry:
5-Chloro-2-methoxybenzenemethanamine is used as a reagent in chemical processes for its versatility in forming different types of chemical bonds, which is crucial for the production of a wide range of chemical products.

InChI:InChI=1/C8H10ClNO/c1-11-8-3-2-7(9)4-6(8)5-10/h2-4H,5,10H2,1H3

Upstream product

• 101079-84-9 4-chloro-1-(chloromethyl)-2-methoxybenzene 
• 78955-90-5 methyl 4-chloro-2-methoxybenzoate 
• 90296-27-8 (4-chloro-2-methoxy-phenyl)methanol 
• 896127-79-0 1-(azidomethyl)-4-chloro-2-methoxybenzene 

Relevant articles and documents

SUBSTITUTED 2,4 DIAMINO-QUINOLINE AS NEW MEDICAMENT FOR FIBROSIS, AUTOPHAGY AND CATHEPSINS B (CTSB), L (CTSL) AND D (CTSD) RELATED DISEASES

The present invention relates to novel 2-primary amino-4-secondary amino-quinoline derivatives, their manufacture, pharmaceutical compositions comprising them and their use as medicaments. The active compounds of the present invention can be useful as a medicament in the treatment and/or the decreasing and/or the prevention of fibrosis and/or fibrosis related diseases, or for use as a medicament in the treatment and/or the decreasing and/or the prevention of the autophagy and/or autophagy related diseases and for the inhibition of the autophagy flux, or for use in the inhibition of cathepsins B (CTSB), L (CTSL) and/or D (CTSD) and/or cathepsins B (CTSB), L (CTSL) and/or D (CTSD) related diseases; with the proviso that said compounds are not to be used for the treatment of any forms of cancers.

3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The invention relates to 3-heterocyclyl indolyl compounds capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, said compounds having the formula (I) wherein R1, R2, R3, R4, RA, Y and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.

HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY

Compounds of formula I depicted below, pharmaceutical compositions containing them, processes for preparing the compounds, and their use in the treatment of obesity, type II diabetes, metabolic syndrome, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy and related conditions, neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease, and pain related disorders. The compounds are melanin concentrating hormone receptor 1 (MCHr1) antagonists.